Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nituzumab plus concurrent chemoradiotherapy for locally advanced laryngopharyngeal squamous cell carcinoma
ChiCTR2100042563Phase 4Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nimotuzumab in Laryngeal squamous cell carcinoma (LSCC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoints: 2-year overall survival rate, 2-year progression-free survival rate and 4 more. Started Jan 2021; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
Laryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on ChiCTR2100042563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042563.